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The angiotensin-converting enzyme (ACE) I/D polymorphism
is an insertion/deletion of an ALU-repeat sequence of 287 base
pairs (bp) in intron 16 of the ACE gene, located at 17q23. This
results in three genotypes: II, ID andDD, with individuals with
the DD genotype having about 40–50% higher circulating
plasma ACE levels than individuals with the II genotype and
individuals with the ID genotype having intermediate levels
[1,2].
ACE plays a role in platelet activation and aggregation and a
reduced ﬁbrinolysis [3]. Increased ACE levels could therefore
theoretically lead to an increased risk of thrombosis, a
hypothesis which is supported by the ﬁnding that ACE-
inhibitors have an antithrombotic effect in rat models [4].
Several studies have focused on the relationship between the
DD genotype and the occurrence of thrombosis. In individuals
following total hip arthroplasty, Philipp et al. found a consid-
erably increased risk of thrombotic events for individuals
carrying the DD genotype compared with individuals carrying
the II genotype [odds ratio (OR) 11.7, 95% conﬁdence interval
(CI): 2.3–84.5] [5]. Subsequent studies yielded conﬂicting
results, with some reporting an increased risk of thrombosis
for individuals with the DD genotype [6–9], and others not
ﬁnding any association between the I/D polymorphism and
thrombosis [10–13].
We investigated the relationship between this polymorph-
ism and deep venous thrombosis (DVT) in a large case–
control study, the Leiden Thrombophilia Study (LETS),
which has been described in detail elsewhere [14]. In short, 474
patients with an objectively conﬁrmed ﬁrst episode of DVT
from three Dutch anticoagulation centers and 474 age- and
sex-matched control subjects from the same geographic area
were enrolled. Subjects with a known malignant disorder
were excluded. The ACE I/D genotype is determined by
polymerase chain reaction, as also described by Rigat et al.
[15]. Results were obtained for 471 cases and 472 control
subjects (see Table 1).
Genotypes of controls were in Hardy–Weinberg equilibrium
(v2 ¼ 0.006, P ¼ 0.94); the frequency of the D-allele among
controls was 0.51, which is consistent with frequencies reported
in other Caucasian populations [16]. The risk estimates, i.e. OR
and 95% CI of the different genotypes, are summarized in
Table 1.
Contrary to expectationswe founda slight protective effect of
the D-allele with regard to deep venous thrombosis (ORDDvs.
II: 0.7,95%CI0.5–1.0).When the subjectswere stratiﬁedbysex,
it became clear that the low overall risk for the D allele was due
almost entirely to a reduced risk in women (DD vs. II women
OR: 0.5, 95% CI: 0.3–0.9; men OR: 0.9, 95% CI 0.5–1.6).
In men, no protective effect of the D-allele was found regardless
of age, but the overall protective effect in women in our study
was found to be restricted to women younger than 50 years of
age (DD vs. II women < 50 years OR: 0.4, 95% CI: 0.2–0.7;
women> 50 years OR: 1.1, 95%CI: 0.4–2.7). Adjustment for
age and several other possible thrombophilic traits (use of an
oral contraceptive, pre/postmenopausal status) did not affect
these results.
Gonzalez Ordonez et al. found a protective effect of the
D allele in Spanish men [11]. Recently, Wells et al. also
reported a protective effect on the risk of venous thrombosis
Table 1 Odds ratio and 95% conﬁdence interval for diﬀerent
insertion/deletion genotypes
Subgroup Genotype
Cases
n ¼ 471
Controls
n ¼ 472 OR (95% CI)
All II 125 112 1*
ID 252 235 1.0 (0.7–1.3)
DD 94 125 0.7 (0.5–1.0)
Men II 55 52 1*
ID 99 100 0.9 (0.6–1.5)
DD 48 49 0.9 (0.5–1.6)
Women II 70 60 1*
ID 153 135 1.0 (0.6–1.5)
DD 46 76 0.5 (0.3–0.9)
*Reference category.
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associated with the D allele, although not signiﬁcant after
restricting to patients with a ﬁrst venous thrombotic event [17].
In the latter study, the protective effect seemed more
pronounced in men than in women, although subgroups were
small. Even though our result is statistically signiﬁcant at the
5% level, the upper limit of the 95% CI approaches 1.0, and
thus a type I error could be the cause, in particular as a
protective effect is difﬁcult to explain.
There are several possible explanations for the diverse results
on the association between the I/D genotype and the risk of
thrombosis. Firstly, the studies varied widely in the types of
patients investigated, e.g. surgery patients [5,10], pregnant
women [6]. Secondly, inclusion criteria differed as to whether
only patients with a ﬁrst event of thrombosis were included
(current study) or patients with a history of thrombosis.
In addition, the studies with smaller numbers of participants
tend to report higher odds ratios than the larger studies. This
could suggest publication bias, but it could also be that in
the speciﬁc subgroups investigated in the smaller studies
(postoperative subjects, African-Americans, pregnant women)
carrying the D allele does indeed result in a higher risk of
developing thrombosis than it does in the larger samples of
unselected patients.
Ethnic background may also play a role. The smaller studies
reporting a high relative riskmainly originated from theUnited
States (sometimes including only, or many African-Ameri-
cans), while larger studies mainly originate from Europe or
Canada. Differences could be due to chance ﬂuctuation, but
perhaps differences in gene–gene and environment–gene inter-
actions play a role.
There is increasing evidence that the I/D polymorphism is
not the functional polymorphism determining ACE levels, but
that it is in LD with a functional variant located more to the 3¢
region of the ACE gene [18–21]. In conclusion, the results of
this study provide insufﬁcient evidence of an association
between the ACE I/D polymorphism and the risk of deep
venous thrombosis.
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